Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Psoriasis (PsO)

In brief

To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad

Key facts

Study ID

NCT07635043

Run by

Pakistan Institute of Medical Sciences

People needed

120

Starts

2026-08-01

Expected to finish

2026-11-30

Last updated by the study team

2026-06-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years-65 years
• Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
• Disease duration of at least 6 months
• Willing and able to provide written informed consent
• Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)

You may not qualify if…

• Severe psoriasis (BSA >20% or requiring systemic therapy)
• Pregnant and lactating mothers
• Known hypersensitivity to Tapinarof or any of its excipients
• Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
• Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment
• History of malignancy or current active infection
• Known hypersensitivity to betamethasone or Tapinarof
• Use of powerful topical corticosteroids within two weeks previously

Where it is running

• Pakistan institute of medical sciences(PIMS) — Islamabad, Federal, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.